Materiały źródłowe

• #1 Myelodysplastic Syndromes Treatment – NCI

  https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq

  Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. […] There are different types of treatment for patients with myelodysplastic syndromes. […] Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplant. […] Patients with a myelodysplastic syndrome who have symptoms caused by low blood counts are given supportive care to relieve symptoms and improve quality of life. Drug therapy may be used to slow progression of the disease. Certain patients can be cured with aggressive treatment with chemotherapy followed by stem cell transplant using stem cells from a donor. […] The following types of treatment are used: Supportive care, Drug therapy, Chemotherapy with stem cell transplant.

• #1 Myelodysplastic Syndromes Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq

  Therapies for myelodysplastic syndromes (MDS) are initiated in patients with a shorter predicted survival or in patients with clinically significant cytopenias. The impact of most MDS therapies on survival remains unproven. […] The mainstay of treatment for MDS has traditionally been supportive care, particularly for patients with symptomatic cytopenias or who are at high risk of infection or bleeding. Transfusions are reserved for the treatment of active bleeding; many centers offer prophylactic platelet transfusions for patients with platelet counts lower than 10,000/mm3. Anemia should be treated with red-cell transfusions to avoid symptoms. […] Lower-risk patients (conventionally defined as International Prognostic Scoring System (IPSS) low-risk and intermediate-1 risk groups) who have failed to respond or have ceased responding to ESAs may be treated with one of several disease-modifying agents. The impact of this practice on survival in lower-risk patients is unknown.

• #1 Diagnosis and Treatment of Myelodysplastic Syndromes: A Review – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36066514/

  Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along with anemia, neutropenia, or thrombocytopenia. […] Therapy for lower-risk MDS is selected based on whether the primary clinical characteristic is anemia, thrombocytopenia, or neutropenia. Management focuses on treating symptoms and reducing the number of required transfusions in patients with low-risk disease. For patients with lower-risk MDS, erythropoiesis stimulating agents, such as recombinant humanized erythropoietin or the longer-acting erythropoietin, darbepoetin alfa, can improve anemia in 15% to 40% of patients for a median of 8 to 23 months. […] For those with higher-risk MDS, hypomethylating agents such as azacitidine, decitabine, or decitabine/cedazuridine are first-line therapy. Hematopoietic cell transplantation is considered for higher-risk patients and represents the only potential cure.

• #1

  https://haematologica.org/article/view/11858

  Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. […] While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient. […] Hypomethylating agents currently remain the only approved non-transplant option for higher-risk MDS and are the standard of care for patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). […] The only potential cure and standard of care for eligible patients is HSCT and even though the number of transplanted especially older MDS patients has increased over time due to better management and greater donor availability, the majority of MDS patients will not be eligible for this curative approach.

• #1 Myelodysplastic syndromes – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/diagnosis-treatment/drc-20366980

  Management of myelodysplastic syndromes is most often intended to slow the disease, ease symptoms and prevent complications. There’s no cure for myelodysplastic syndromes, but some medications can help slow the progression of the disease. […] Blood transfusions with healthy blood cells from donors can be used to replace red blood cells and platelets in people with myelodysplastic syndromes. Blood transfusions can help control symptoms. […] Treatment for myelodysplastic syndromes might include medications that: […] A bone marrow transplant, also known as a stem cell transplant, is the only treatment option that offers the potential of a cure for myelodysplastic syndromes. But this treatment carries a high risk of serious complications and it’s generally reserved for people who are healthy enough to endure it.

• #1 Myelodysplastic Syndrome (MDS) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

  Treatment with azacitidine or decitabine may help; if acute myeloid leukemia supervenes, it is treated per the usual protocols. […] In general, treatment is reserved for symptomatic patients. […] Symptomatic patients usually require chronic blood and platelet transfusions. These patients subsequently often develop secondary iron overload. Patients with lower-risk myelodysplastic syndrome and serum ferritin level 1,000 ng/mL ( 1,000 mcg/L) may benefit from iron chelation. […] Erythrocyte-stimulating agents (ESA) decrease the severity of anemia in 15 to 20% of patients with MDS, particularly in anemic patients who are not dependent on transfusions and have a serum erythropoietin level Luspatercept has been successful in increasing the hematocrit in patients with very low to intermediate-risk MDS with ringed sideroblasts in whom ESA therapy has failed.

• #1 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Myelodysplastic syndrome (also called myelodysplasia or MDS) affects blood stem cells. MDS treatment focuses on keeping it from getting worse. […] If you have MDS, your healthcare providers will focus treatment on slowing its progress, easing your symptoms and treating the conditions it causes. […] Healthcare providers consider several factors when developing MDS treatment plans: The type of MDS you have. If you have MDS conditions such as anemia, bleeding or infections. Whether you developed MDS after receiving chemotherapy or radiation therapy for cancer. Your age. Your general health. […] Treatment for myelodysplastic syndrome may include supportive care and treatment to get rid of unhealthy blood cells. Supportive care may include: Blood transfusion: If you have anemia, you may receive red blood cell transfusions. If you have bleeding issues, you may receive platelet transfusions. Erythropoiesis-stimulating agents (ESA): This treatment boosts your mature red blood cell levels. Antibiotics: MDS may affect your white blood cells and increase your risk of infections.

• #1 How We Treat Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/treatment

  Immunomodulating drugs such as lenalidomide is often used for patients with low-grade MDS, and is especially effective in patients who have MDS-del(5q), where a piece of chromosome 5 is missing in MDS cells. […] Supportive care includes transfusions of blood products to address low blood cell counts that MDS patients experience. Some patients may also receive growth factor injections to help the bone marrow make new blood cells. […] For some patients with MDS, allogeneic stem cell/bone marrow transplant can be an effective treatment. […] Together with colleagues, Corey Cutler, MD, MPH, FRCPC, led the BMT CTN 1102 study, which found that MDS patients who undergo reduced-intensity stem cell transplant with a suitable donor achieve better outcomes than MDS patients who do not have a suitable stem cell donor and therefore receive drug therapy alone.

• #1 Treatment Options for Low-Risk Myelodysplastic Syndrome

  https://www.targetedonc.com/view/treatment-options-for-low-risk-myelodysplastic-syndrome

  For patients who predominantly have problems with low white [blood cell] count and low neutrophils, putting them at a high risk of infection, then using growth factors that stimulate white cells, such as Neupogen [filgrastim] and Neulasta [pegfilgrastim], could be considered. […] For this hypoplastic/aplastic MDS sort of scenario, we can use immunosuppressive therapy like cyclosporine, cyclosporine/ATG [antithymocyte globulin], cyclosporine/ATG/steroids; they seem to work quite well. […] These patients seem to respond very well to an oral therapy called lenalidomide or Revlimid. […] Bone marrow transplant, also called allogeneic stem cell transplant, is really the only curative option for MDS and in AML, both in low risk and high risk. However, this procedure is a very major procedure. […] We are now learning that even those patients who are at lower risk due to having lower blasts and not as severe cytopenias, may still have mutations like TP53, EZH, and RUNX1, that could actually put them at a higher predictive risk of transformation.

• #1 Myelodysplastic Syndrome (MDS) Treatment & Management: Approach Considerations, Supportive Care, Pharmacologic Therapy

  https://emedicine.medscape.com/article/207347-treatment

  Treatment with hypomethylating agents (ie, azacytidine, decitabine) is considered standard therapy for both low-risk MDS cases without 5q-, as well as intermediate and high-risk MDS. This approach is especially useful in elderly patients, who experience high rates of morbidity and mortality with cytotoxic chemotherapy. […] Patients with MDS should be under the care of a hematologist. Because most treatments for MDS are not standard and are considered experimental, referral to a tertiary care center with bone marrow transplantation capabilities is often necessary. […] Although treatment of symptoms improves quality of life in MDS, these measures are temporary. More long-term measures are necessary to stimulate the patient’s bone marrow production of mature blood cells. Practitioners are encouraged to refer patients for participation in clinical trials at academic centers and the MDS Centers of Excellence.

• #1 Myelodysplastic Syndrome (MDS) Treatment & Management: Approach Considerations, Supportive Care, Pharmacologic Therapy

  https://emedicine.medscape.com/article/207347-treatment

  Cytotoxic chemotherapy is used in patients with MDS with increasing myeloblasts and those who have progressed to acute leukemia. The usual combination treatment is a cytarabine-anthracycline combination, which yields a response rate of 30-40% (high complication rate and morbidity in elderly patients). […] Lenalidomide is the drug of choice in MDS with 5q deletion syndrome. In particular, patients with the karyotype characterized by deletion 5q31 show the best response. […] Azacitidine and decitabine are the two hypomethylating agents currently used in the treatment of MDS. Azacitidine and decitabine may reduce hypermethylation and induce re-expression of key tumor suppressor genes in MDS. […] In a pivotal trial that included patients in all stages of MDS, patients treated with azacitidine showed a 37% response (7% complete response, 16% partial response) versus a 5% response in the control arm, with an improved median time to transformation or death (21 mo for azacitidine vs 13 mo for controls) and transformation to leukemia (15% for azacitidine vs 38% for controls).

• #1 Myelodysplastic Syndrome (MDS): Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/207347-overview

  Standard care for MDS is constantly changing, but it typically includes supportive therapy, including transfusions, and may include bone marrow stimulation and cytotoxic chemotherapy or hypomethylating agents. Bone marrow transplantation has a limited role. (See Treatment.) […] Using artificial intelligence, Razha and colleagues developed a personalized prognostic model for patients with MDS that is based on clinical and genomic data. […] The IPSS-M has six risk categories: very low, low, moderate low, moderate high, high, very high). The score can be used for determining clinical trial eligibility criteria, correlative studies, and treatment recommendations. […] FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes. […] FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home.

• #1 Myelodysplastic Syndrome (MDS) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

  Drugs used to treat MDS include Azacitidine, Decitabine, and Lenalidomide. […] Azacitidine is a pyrimidine nucleoside analog. Azacitidine prolongs overall survival compared with supportive care and conventional chemotherapy. Median survival in patients with all subgroups of MDS treated with azacitidine is 21 months. Patients should be treated for at least of 4 to 6 cycles and continue for as long as the patient continues to benefit. […] Decitabine is also a pyrimidine nucleoside analog. It induces remission in as many as 43% of patients with MDS. It is indicated for treatment of patients with MDS of all subtypes. […] Azacitidine and decitabine are epigenetic modulators that hypomethylate DNA. Hypermethylation of certain regions of DNA appears to impair tumor suppressor genes and play a role in oncogenesis in MDS.

• #1 Medicines for Myelodysplastic Syndromes | MDS Drug Treatments | American Cancer Society

  https://www.cancer.org/cancer/types/myelodysplastic-syndrome/treating/chemotherapy.html

  Some medicines can help treat MDS by affecting the body’s immune system. […] Lenalidomide (Revlimid) belongs to a class of drugs known as immunomodulating drugs (IMiDs). […] This drug seems to work best when the MDS cells are missing a part of chromosome 5. […] Drugs that suppress the immune system can help some people with lower-risk MDS. […] In some people with MDS, the cancer cells have a change (mutation) in the IDH1 gene, which normally helps cells make the IDH1 protein. […] Ivosidenib (Tibsovo) is an IDH1 inhibitor.

• #1 Myelodysplastic Syndrome (MDS) Treatment & Management: Approach Considerations, Supportive Care, Pharmacologic Therapy

  https://emedicine.medscape.com/article/207347-treatment

  Patients with lower-risk MDS and anemia in whom therapy with an erythropoietin-stimulating agent (ESA) is not effective generally become dependent on RBC transfusions. Luspatercept is a recombinant fusion protein that promotes RBC maturation by binding several endogenous transforming growth factor (TGF) superfamily ligands, thereby diminishing Smad2/3 signaling. […] On June 6, 2024, the FDA approved imetelstat (Rytelo), an oligonucleotide telomerase inhibitor, for adults with transfusion-dependent MDS who have not responded to, have lost response to, or are ineligible for ESAs.

• #1 Myelodysplastic Syndromes (MDS) | UH Seidman Cancer Center | University Hospitals | University Hospitals

  https://www.uhhospitals.org/services/cancer-services/hematologic-malignancy/leukemia/myelodysplastic-syndromes

  Treatment of myelodysplastic syndromes usually focuses on slowing the progression of the disease, relieving symptoms and preventing complications. […] Treatment options include: Blood transfusion Red blood cells and platelets in people with a myelodysplastic syndrome can be replaced with healthy blood cells from donors to help control symptoms of MDS. […] Medication therapy for myelodysplastic syndromes may include some combination of the following: Erythropoiesis-stimulating agents (ESAs) and other growth factors: ESAs are used to increase the number of mature red blood cells that the body can produce and reduce the effects of anemia. […] Luspatercept: This medication is indicated for the treatment of anemia in certain MDS patients who need regular red blood cell transfusions but have not responded well to ESA therapy or cannot receive ESAs.

• #1 Myelodysplastic Syndrome (MDS) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

  Lenalidomide is an immunomodulator that is effective in reducing red blood cell transfusion requirements in patients with MDS with deletion 5q syndrome. […] In patients with hypoplastic MDS, immunosuppression with cyclosporine with or without antithymocyte globulin (ATG) has been effective, as evidenced by cell count improvement and decreased need for transfusion. […] Allogeneic hematopoietic stem cell transplantation is the only curative treatment for MDS. Allogeneic hematopoietic stem cell transplantation is indicated in younger, medically fit patients generally in intermediate-2 and high risk groups.

• #1 Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics

  People with lower-risk MDS are generally treated with low-intensity therapy or supportive care alone. […] Treatment of people with higher-risk MDS may vary according to age, overall health, and personal preference: […] People who are less than about 75 years old and otherwise healthy may be treated with low- or high-intensity therapies. […] People who are about 75 years or older or less medically fit may be treated with low-intensity therapy or supportive care alone. However, there is no absolute age cut-off at which high-intensity therapy is no longer recommended. […] There is great interest in clinical trials for improving treatment of MDS. […] LOW-INTENSITY TREATMENTS […] Low-intensity chemotherapy—Certain classes of drugs, or low doses of drugs from other classes, may be suggested for people with lower-risk MDS, or for people with higher-risk MDS who cannot tolerate high-intensity treatments. The goal is to enable bone marrow cells to develop more normally and allow improved production of red blood cells, white blood cells, and platelets. Drugs used in this situation include luspatercept, imetelstat, azacitidine, decitabine, decitabine/cedazuridine, and lenalidomide.

• #1 Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics

  HIGH-INTENSITY TREATMENTS […] High-intensity chemotherapy—People with higher-risk MDS may be treated with low-intensity chemotherapy drugs azacitidine, decitabine, or decitabine/cedazuridine, or with chemotherapy similar to that used for treating acute myeloid leukemia (AML). Chemotherapy is used to destroy abnormal cells or prevent them from growing. For people who are eligible, this may be followed by a stem cell transplant because intensive chemotherapy alone is unlikely to cure MDS. […] Stem cell transplantation—Stem cell transplantation (also called hematopoietic cell transplantation or bone marrow transplantation) is the treatment for MDS most associated with long-term survival, although long-term survivors can have complications such as „graft-versus-host disease” (GVHD). As with all therapies, the potential risks of transplant must be considered together with the potential benefits relative to other treatment options.

• #1 Treatment for Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/treatment

  If you have been diagnosed with myelodysplastic syndrome (MDS), Memorial Sloan Kettering doctors will devise a course of treatment specific to you. We will take a number of factors into consideration, including: […] If you have been diagnosed with MDS, you may be able to receive a stem cell transplant, also called a bone marrow transplant. It has the potential to cure MDS. […] Stem cell transplants may be considered as a treatment option if you are below the age of 75 and are otherwise healthy. […] Supportive care is the cornerstone of all MDS treatments. Its goal is to help alleviate or prevent symptoms from low blood counts. […] Treatments may help improve blood counts temporarily and reduce or eliminate symptoms from low blood counts. They do not fix the underlying cause of MDS.

• #1 Myelodysplastic Syndromes Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq

  Allogeneic HSCT is the only potentially curative treatment for MDS. Retrospective data suggest cure rates in selected patients ranging from 30% to 60%; outcomes varied with IPSS score at time of transplant, with inferior survival in patients with higher IPSS scores. […] In the absence of prospective data, therapy-related myeloid neoplasms are treated similarly to de novo MDS.

• #1 Intensive treatment for MDS | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/myelodysplastic-syndromes-mds-/mds-treatment-side-effects/intensive-treatment/

  Intensive treatment for MDS usually means having intensive chemotherapy followed by a stem cell transplant. The aim is to get rid of the MDS, so your bone marrow can work normally again. […] Intensive chemotherapy is a treatment option for some people with high risk MDS. The aim is to kill as many of the abnormal cells in the bone marrow as possible. […] For this reason, your doctor will usually offer you intensive chemotherapy followed by a stem cell transplant. This gives the best chance of the MDS being cured. […] A stem cell transplant gives the best chance of curing MDS. The type of stem cell transplant used for people with MDS is called an allogeneic transplant. It replaces the stem cells in your bone marrow with healthy stem cells from someone else (a donor). […] A stem cell transplant is an intensive treatment that can have serious complications. So they are only recommended for people who are fit enough to go through the treatment, and when the benefits outweigh the risks.

• #1 Treatment for myelodysplastic syndrome (MDS) – NHS

  https://www.nhs.uk/conditions/myelodysplastic-syndrome-mds/treatment/

  Myelodysplastic syndrome (MDS) often develops very slowly. You may not need treatment straight away. […] Treatment will depend on: your symptoms, the type of MDS you have, how quickly your symptoms are expected to get worse, and the risk of MDS developing into acute myeloid leukaemia (the risk group), your age, your general health. […] If you have low risk MDS and few symptoms you’ll usually just have regular check-ups, including blood tests. You may need treatment in the future if your condition gets worse. […] If you have higher risk MDS, treatment may include chemotherapy or a stem cell transplant. You may also have medicines called immunosuppressants, targeted medicines or immunotherapy. […] You’ll also have treatments to prevent and manage symptoms (called supportive treatments).

• #1 Myelodysplastic neoplasms (MDS) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myelodysplastic-syndromes/

  Your haematologist will recommend treatment based on: […] Your treatment team will discuss your type of MDS and your treatment options. […] Watch and wait (active observation) involves regular monitoring. This includes blood tests and general health. No intervention is needed unless the person develops signs and symptoms the MDS it is progressing. […] Supportive care controls symptoms of MDS and side effects. Supportive care aims to improve quality of life. It is frequently used for older people or those with other health problems. This group of people are often unable to tolerate the stronger treatments for MDS. Supportive care does not aim to treat the disease. It can help with symptoms such as shortness of breath, bruising or bleeding. […] Targeted therapy directly targets the mutations/changes inside the blood cancer cells. It also slows down the growth or speeds up the rate at which the blood cancer cells die. For MDS it works in several ways:

• #1 Treatment recommendations developed by MDS experts of the Polish Adult Leukemia Group (PALG) for management of myelodysplastic syndromes (MDSs) and other MDS-related conditions in Poland for 2021 | Mądry | Acta Haematologica Polonica

  https://journals.viamedica.pl/acta_haematologica_polonica/article/view/AHP.a2022.0009

  Treatment response is assessed according to the International Working Group (IWG) 2006 criteria, modified in 2018 for MDS-LR patients. Such responses include increases in blood cell count, reductions in the number of transfusions or transfusion independence, and reductions in bone marrow blasts percentages. […] Erythropoiesis-stimulating agents (ESAs) are recommended as first-line treatment in MDS-LR patients with symptomatic anemia and Hb levels below 10 g/dL. Erythropoietin alpha has been registered in the European Union in this indication, and darbepoetin (approved only in the United States) is widely used in Poland and other European countries. […] The Polish Adult Leukemia Group (PALG) MDS working groups indications for the treatment of ESA G-CSF are as follows patients in MDS LR group according to IPSS with symptomatic anemia (regardless of RBC-TD although it is optimal to start treatment before RBC transfusion demand is 2 units/month) and EPO level 500 U/L.

• #1 New Treatment Approved for Certain Patients Living With Myelodysplastic Syndromes < Yale School of Medicine

  https://medicine.yale.edu/news-article/new-treatment-approved-for-certain-patients-living-with-myelodysplastic-syndromes/

  The U.S. Food and Drug Administration has approved imetelstat (known commercially as RYTELO) to treat some patients with the rare blood cancer, myelodysplastic syndromes (MDS). […] The trial showed that imetelstat, a first-in-class telomerase inhibitor, leads to durable independence from red blood cell transfusions and a significant improvement in anemia for heavily transfused lower-risk MDS patients. […] RYTELO is for adult patients with low- to intermediate-1 risk MDS, who are transfusion-dependent and require four or more red blood cell units over eight weeks. […] The new treatment aims to impede cancer growth for these patients with MDS, which affects mostly adults over 60 who are male.

• #1 Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape

  https://www.mdpi.com/1718-7729/31/4/148

  Erythropoietin (EPO), an ESA, is an established treatment modality for anemia in patients with lower-risk MDS. […] Lenalidomide is an immunomodulatory agent with multiple mechanisms of action and is effective in the presence of del(5q). […] Hypomethylating agents (HMAs) are currently used in AML for transplant-ineligible patients who are not candidates for intensive chemotherapy. HMA therapy is also well established as frontline treatment in patients with high-risk MDS, as discussed in subsequent sections. […] Allo HSCT remains the only potentially curative treatment option for MDS and is the recommended standard of care for any suitable higher-risk candidate. […] With ongoing research, we anticipate that clinical, laboratory and molecular data will be increasingly utilized in clinical decision making, ultimately leading to more effective and less toxic targeted interventions as we work to decrease morbidity and improve survival for our patients with MDS.

• #1 3 Innovative Myelodysplastic Syndrome Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/myelodysplastic-syndrome/myelodysplastic-syndrome-treatment.html

  Lower-risk myelodysplastic syndrome patients are treated initially for the specific complications of the disease, such as anemia and low blood counts. If more aggressive therapy is needed, strategies that are considered standard of care include chemotherapy using hypomethylating agents (5-azacitidine and decitabine) and lenalidomide. […] Higher-risk myelodysplastic syndrome patients usually need more aggressive therapy, but much depends on the age and condition of the patient. Younger patients with high-risk disease are considered for front-line chemotherapy approaches followed perhaps by allogeneic stem cell transplantation. […] For older patients, intensive chemotherapy is rarely considered. Instead, our strategy focuses on development of active and safe treatments for newly diagnosed patients as well as those for whom the standard of care based therapies has not been effective.

• #1

  https://haematologica.org/article/view/11858

  HMA are the only approved first-line treatment for higher-risk MDS. […] The hematologic response rate to HMA is about 40% but treatment rarely leads to complete remission (8%) and most patients eventually relapse. […] The outcome of HR-MDS patients in whom HMA fail is poor. […] Allogeneic HSCT is currently the standard-of-care treatment for HR-MDS patients eligible for the procedure and the only curative treatment but its inherent therapy-related morbidity and mortality necessitate careful selection of patients. […] Despite patients with TP53 mutations having a worse outcome after HSCT than patients without these mutations, post-hoc analysis of data from the BMT-CTN 1102 trial showed that, compared to non-transplant approaches, HSCT improved survival for TP53 single-hit patients, TP53 multi-hit patients and IPSS-M high-risk patients without TP53 mutation. […] Treatment of HR-MDS remains a major challenge. […] For patients who are not eligible for transplantation, treatment options are limited and HMA remain the standard treatment.

• #1 Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective | Leukemia

  https://www.nature.com/articles/s41375-023-01864-6

  In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. […] This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p0.001). […] T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. […] A higher proportion of t-MDS patients were found in the high (24%) and very high (26%) Revised International Prognostic Scoring System (IPSS-R) groups compared to de novo-MDS (15% and 14%, respectively) (p0.001), a major contributing factor was the large number of t-MDS patients with high-risk cytogenetics (39% with poor or very poor cytogenetic risk group).

• #1 Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective | Leukemia

  https://www.nature.com/articles/s41375-023-01864-6

  In patients with t-MDS, 56% had been treated with chemotherapy only for their primary disease, 25% with radiation only and 19% with both. […] The median OS of t-MDS was 15.8 months, compared to 31.1 months for de novo-MDS (p0.001). […] Patients treated with chemotherapy or chemotherapy and radiation in combination had significantly shorter survival (13.3 and 9.0 months, respectively) than patients treated with radiation only (34.8 months) (p0.001). […] T-MDS patients with a previous non-malignant disease and a previous solid tumor had longer OS, (26.1 and 22.3 months) compared with patients with a history of a hematological malignancy (9.0 months) (p0.001). […] Our results show that mortality from the primary disease is substantial, with the highest mortality observed in patients with a previous hematological malignancy. […] This group of patients have a dismal prognosis with only nine months median OS. […] Based on our findings we can conclude that both primary disease and type of cytotoxic treatment strongly influence survival and that these additional variables should be considered in the prognostication of t-MDS.

• #1 Treating Myelodysplastic Syndromes | MDS Treatment | American Cancer Society

  https://www.cancer.org/cancer/types/myelodysplastic-syndrome/treating.html

  Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-of-the-art cancer treatment. […] You may hear about alternative or complementary methods to relieve symptoms or treat your cancer that your doctors havent mentioned. […] Be sure to talk to your cancer care team about any method you are thinking about using. They can help you learn what is known (or not known) about the method, which can help you make an informed decision. […] Whether you are thinking about treatment, getting treatment, or not being treated at all, you can still get supportive care to help with pain or other symptoms. […] For some people, when treatments have been tried and are no longer controlling the cancer, it could be time to weigh the benefits and risks of continuing to try new treatments. […] Remember that even if you choose not to treat the cancer, you can still get supportive care to help with pain or other symptoms.

• #1 Myelodysplastic Syndrome (MDS) Center | Hematology | Stanford Medicine

  https://med.stanford.edu/hematology/patient_care/mdscenter.html

  Currently active clinical trials for MDS may be viewed under MDS protocols on the Hematology Division Clinical Trials page. […] Therapy for lower risk patients: Splice gene modulator (H3B-8800) treatment of splice gene mutated MDS and CMML patients […] Luspatercept treatment of sideroblastic anemia MDS patients […] Therapy for higher risk patients: Aprea-246 treatment of TP53 mutated MDS and CMML patients […] Splice gene modulator (H3B-8800) treatment of splice gene mutated MDS and CMML patients […] Bone marrow transplantation.

• #1 How We Treat Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/treatment

  New research shows stem cell transplant represents the best therapeutic approach for older individuals with a pre-leukemia state called myelodysplastic syndrome. […] Our team has led many MDS clinical trials, including the multicenter trial that led to the FDA approval of the most commonly used schedule of decitabine for MDS. […] We continue to pursue new approaches for treating MDS through clinical trials. One novel approach uses the BCL-2 inhibitor venetoclax in MDS treatment. […] Through our Edward P. Evans Center for Myelodysplastic Syndromes, our clinicians and scientists continue transformative collaborative research aimed at treating, preventing, and ultimately curing MDS.

• #1 Treating myelodysplastic syndrome (MDS) : University College London Hospitals NHS Foundation Trust

  https://www.uclh.nhs.uk/our-services/find-service/cancer-services/blood-diseases-clinical-haematology/blood-diseases-types-and-services/blood-cancers/myelodysplastic-syndrome-mds/treating-myelodysplastic-syndrome-mds

  We are currently running a study called REPAIR MDS, which is for patients who have not responded to standard treatment with EPO and require transfusion. […] These studies are designed for patients with intermediate or higher risk MDS and compares the current standard of care in these patients (azacitidine – Vidaza) with azacitidine in combination with a new drug called duvalumab, which works by enhancing the immune system’s ability to see MDS cells. […] UCLH has a phase I clinical trial unit. Haematology trials are run by Dr Jenny O’Nions. Phase I trials are usually for patients that we do not have any further licenced treatments available for. This is because these are often very new drugs that we do not know whether they will be effective or not. Several of these studies are open to patients with MDS please see the CRF website for further details.

• #1 Myelodysplastic Syndromes | Symptoms, Treatments, FAQs | LLS

  https://www.lls.org/myelodysplastic-syndromes/myelodysplastic-syndromes

  Hematologists and oncologists are specialists who treat people who have MDS or other types of blood cancer. […] Treatment outcomes vary widely among patients; results depend on many individual factors. […] Seek treatment in a cancer center where doctors are experienced treating patients with MDS. […] Ask your doctor whether a clinical trial is a good treatment option for you.

• #1 Treating Myelodysplastic Syndromes | MDS Treatment | American Cancer Society

  https://www.cancer.org/cancer/types/myelodysplastic-syndrome/treating.html

  If youve been diagnosed with a myelodysplastic syndrome (MDS), your treatment team will discuss your options with you. Its important to weigh the benefits of each treatment option against the possible risks and side effects. […] The main types of treatment for MDS are: Supportive Therapy for Myelodysplastic Syndromes (MDS), Medicines for Myelodysplastic Syndromes (MDS), Stem Cell Transplant for Myelodysplastic Syndrome (MDS). […] Treatment is based on the type of MDS, MDS risk group and other factors, as well as your age and overall health. Often more than one type of treatment is used. Doctors plan each persons treatment individually to give them the best chance of treating the tumor while limiting the side effects as much as possible. […] Its important to discuss all treatment options, including their goals and possible side effects, with your doctors to help make the decision that best fits your needs.

• #1 How We Treat Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/treatment

  Patients with MDS are cared for by an experienced team in the Adult Leukemia Program. Our specialists care for a large number of MDS patients and use their deep expertise to develop treatment plans for each individual patient. […] Treatment for MDS may include chemotherapy, targeted therapy with novel agents, supportive care, and/or stem cell/bone marrow transplant. The goals of treatment are to: […] Our team has extensive experience developing care plans with standard and novel therapies to ensure the best possible outcomes. […] Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells by either eliminating the cells or stopping them from dividing. Common chemotherapy drugs for MDS include azacitidine and decitabine. […] Novel agents are often targeted drugs or other substances that identify and attack specific cancer cells without harming normal cells. Luspatercept is an example of a novel agent used for MDS.

• #1 Myelodysplastic syndromes | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/leukemia/what-is-leukemia/myelodysplastic-syndromes

  Myelodysplastic syndromes (MDSs) are a group of diseases where the bone marrow does not make enough healthy blood cells. Instead the bone marrow makes immature blood cells, called blast cells (blasts), that do not work properly. They build up in the bone marrow and the blood and crowd out healthy blood cells. As a result, there are fewer healthy red blood cells, white blood cells and platelets. […] The goal of treatment for an MDS is to relieve symptoms, slow or stop the MDS from developing into AML and improve quality of life. […] Your healthcare team will work with you to create a treatment plan, which may include treating the symptoms or complications from the MDS (called supportive therapy), like low blood cell counts, or treating the disease itself. […] Supportive therapy may include: transfusions, growth factors, drug therapy.

• #1 Myelodysplastic syndrome: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007716.htm

  Myelodysplastic syndrome (MDS) is a form of cancer. In about a third of people, MDS may develop into acute myeloid leukemia (AML). […] The goal of MDS treatment is to prevent leukemia from developing and to prevent problems due to a shortage of blood cells, infections and bleeding. It may consist of: […] Your provider may try one or more treatments to see what your MDS responds to.

• #2 Treating Myelodysplastic Syndromes | MDS Treatment | American Cancer Society

  https://www.cancer.org/cancer/types/myelodysplastic-syndrome/treating.html

  If youve been diagnosed with a myelodysplastic syndrome (MDS), your treatment team will discuss your options with you. Its important to weigh the benefits of each treatment option against the possible risks and side effects. […] The main types of treatment for MDS are: Supportive Therapy for Myelodysplastic Syndromes (MDS), Medicines for Myelodysplastic Syndromes (MDS), Stem Cell Transplant for Myelodysplastic Syndrome (MDS). […] Treatment is based on the type of MDS, MDS risk group and other factors, as well as your age and overall health. Often more than one type of treatment is used. Doctors plan each persons treatment individually to give them the best chance of treating the tumor while limiting the side effects as much as possible. […] Its important to discuss all treatment options, including their goals and possible side effects, with your doctors to help make the decision that best fits your needs.

• #2 Treatment recommendations developed by MDS experts of the Polish Adult Leukemia Group (PALG) for management of myelodysplastic syndromes (MDSs) and other MDS-related conditions in Poland for 2021 | Mądry | Acta Haematologica Polonica

  https://journals.viamedica.pl/acta_haematologica_polonica/article/view/AHP.a2022.0009

  The choice of treatment for patients with myelodysplastic syndromes (MDS) is determined by the level of risk of transformation into acute myeloid leukemia (AML), as well as by the predicted overall survival time according to the prognostic scoring systems International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring System (IPSS-R). […] The goal of treatment in lower-risk patients is to obtain hematological improvement, and the quality of life (QoL) improvement that comes with that. Taking into account the relatively favorable prognosis, and the toxicity of therapy, aggressive treatment is not usually used in this population. […] In higher-risk patients, depending on their general condition and the biological characteristics of the underlying disease, palliative or disease-modifying treatments (i.e. hypomethylating agents, chemotherapy) are used with the intention of prolonging survival and improving QoL or even as curative treatment [e.g. allogeneic hematopoietic stem cell transplantation (allo-HSCT)].

• #2

  https://www.accc-cancer.org/home/learn/cancer-types/hematologic-malignancies/myelodysplastic-syndromes

  Myelodysplastic syndromes (MDS) constitute a rare category of bone marrow disorders. The treatment approach for MDS varies based on risk groups. For low-risk patients, treatment is aimed at reducing transfusion dependence, alleviating cytopenias, and enhancing quality of life. In contrast, high-risk patients require a different strategy, focusing on delaying leukemic progression and prolonging survival. This initiative involved a comprehensive review of risk stratification, identifying optimal management of anemia specifically in the high-risk group, and addressing barriers faced by patients with high-risk MDS. […] More than two thirds of MDS patients fall in the low-risk category, with anemia as the most common symptom. This initiative consists of two phases that aim at providing support and guidance for healthcare professionals in effectively managing anemia in patients with low-risk MDS.

• #2

  https://haematologica.org/article/view/11858

  Current challenges include decreasing the relapse risk, the main cause of HSCT failure. […] The management and treatment of HR-MDS should start with a thorough diagnostic and prognostic assessment including molecular and cytogenetic work-up. […] Even if patients can be classified as low risk according to the available MDS risk scores, the disease is a blood cancer with an overall poor prognosis. […] If a cure is not possible with available therapies, all other options, including survival prolongation, should be associated with an improved quality of life. […] Supportive care is crucial in the management of patients with MDS, independently of whether they have low- or high-risk disease, and consists of active disease monitoring, transfusion support, and other aspects of dealing with cytopenias and increased risk of infection and bleeding.

• #2 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Myelodysplastic syndrome (also called myelodysplasia or MDS) affects blood stem cells. MDS treatment focuses on keeping it from getting worse. […] If you have MDS, your healthcare providers will focus treatment on slowing its progress, easing your symptoms and treating the conditions it causes. […] Healthcare providers consider several factors when developing MDS treatment plans: The type of MDS you have. If you have MDS conditions such as anemia, bleeding or infections. Whether you developed MDS after receiving chemotherapy or radiation therapy for cancer. Your age. Your general health. […] Treatment for myelodysplastic syndrome may include supportive care and treatment to get rid of unhealthy blood cells. Supportive care may include: Blood transfusion: If you have anemia, you may receive red blood cell transfusions. If you have bleeding issues, you may receive platelet transfusions. Erythropoiesis-stimulating agents (ESA): This treatment boosts your mature red blood cell levels. Antibiotics: MDS may affect your white blood cells and increase your risk of infections.

• #2 How I Treat Anemia Associated with Lower-Risk Myelodysplastic Syndromes

  https://jhoponline.com/issue-archive/2021-issues/june-2021-vol-11-no-3/how-i-treat-anemia-associated-with-lower-risk-myelodysplastic-syndromes

  Myelodysplastic syndromes (MDS) are a heterogenous group of acquired bone marrow disorders, with a median age of 70 years at diagnosis. The treatment options are often limited at this age, because of the intensity of therapy. […] The most common objective sequalae of MDS is anemia, which occurs in approximately 80% to 85% of patients. […] Red blood cell transfusions are a cornerstone of supportive care for MDS-related anemia. […] However, such transfusions also lead to iron overload, which negatively affects the function of the liver, heart, and the endocrine system. […] The current treatment options for anemia associated with lower-risk MDS discussed include lenalidomide; erythropoiesis-stimulating agents (ESAs), with or without granulocyte colony-stimulating factors (G-CSFs); luspatercept; transfusion; and iron chelation for patients with iron overload.

• #2 Tests and treatment for myelodysplastic syndrome | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/myelodysplastic-syndromes/treatment

  You may have transfusions to treat your MDS. You have a drip containing red blood cells if your red blood cells are low. If your platelets are low you have a drip of a clear fluid containing platelets. […] Growth factors are drugs that encourage your bone marrow to make more blood cells. We know from research that this can reduce the number of blood transfusions you need. […] Sometimes with MDS, white blood cells called T lymphocytes affect normal blood cell production. Immunosuppressant drugs work by making T lymphocytes less active. […] Chemotherapy uses drugs to destroy the immature cells. The drugs work by disrupting the growth of cells and stopping them from dividing. […] When you have a stem cell transplant using another persons (donor) stem cells, it is called an allogeneic transplant.

• #2 Treatment Options for Low-Risk Myelodysplastic Syndrome

  https://www.targetedonc.com/view/treatment-options-for-low-risk-myelodysplastic-syndrome

  For low-risk MDS [myelodysplastic syndrome], the goal of treatment is to improve the blood [cell] counts. The goal of treatment of low-risk MDS is really to reset the bone marrow by removing or reducing the dysplastic changes as much as possible and stimulating the production of normal red cells, platelets, and white [blood] cells. The treatments are usually a very low intensity therapy because we’re not really trying to kill large amounts of leukemia or cancer cells here, but it’s really more treatment to reset the bone marrow. Erythropoietin is a hormone that helps stimulate hemoglobin; if the erythropoietin level is less than 500 [mU/mL], we can often use growth factors called erythropoietin-stimulating agents. Drugs like Procrit [epoetin alfa], Aranesp [darbepoetin alfa], and others can help bring the hemoglobin up in about 50% to 60% of patients and make them transfusion independent.

• #2 Myelodysplastic Syndromes (MDS) | UH Seidman Cancer Center | University Hospitals | University Hospitals

  https://www.uhhospitals.org/services/cancer-services/hematologic-malignancy/leukemia/myelodysplastic-syndromes

  Lenalidomide: Patients who have a MDS associated with an isolated del(5q) chromosome abnormality and who require frequent red blood cell transfusions may be prescribed lenalidomide (Revlimid), which is a medication used to reduce the need for red blood cell transfusions. […] Azacitidine and decitabine: These medications are used to treat MDSs by destroying abnormal cells that divide rapidly. […] Immunosuppressive therapy: Used to suppress or control the immune system, these medications are indicated for the treatment of certain MSDSs. […] Antibiotic therapy: Antibiotics may be administered to fight infection. […] Chemotherapy: Chemotherapy uses drugs to kill cancer cells. […] A bone marrow transplant, also known as a stem cell transplant, is the only treatment option that can potentially cure MDSs. […] Because a bone marrow transplant carries a high risk of complications, this procedure is reserved for patients deemed healthy enough to endure it.

• #2

  https://haematologica.org/article/view/11858

  HMA are the only approved first-line treatment for higher-risk MDS. […] The hematologic response rate to HMA is about 40% but treatment rarely leads to complete remission (8%) and most patients eventually relapse. […] The outcome of HR-MDS patients in whom HMA fail is poor. […] Allogeneic HSCT is currently the standard-of-care treatment for HR-MDS patients eligible for the procedure and the only curative treatment but its inherent therapy-related morbidity and mortality necessitate careful selection of patients. […] Despite patients with TP53 mutations having a worse outcome after HSCT than patients without these mutations, post-hoc analysis of data from the BMT-CTN 1102 trial showed that, compared to non-transplant approaches, HSCT improved survival for TP53 single-hit patients, TP53 multi-hit patients and IPSS-M high-risk patients without TP53 mutation. […] Treatment of HR-MDS remains a major challenge. […] For patients who are not eligible for transplantation, treatment options are limited and HMA remain the standard treatment.

• #2 Treatment recommendations developed by MDS experts of the Polish Adult Leukemia Group (PALG) for management of myelodysplastic syndromes (MDSs) and other MDS-related conditions in Poland for 2021 | Mądry | Acta Haematologica Polonica

  https://journals.viamedica.pl/acta_haematologica_polonica/article/view/AHP.a2022.0009

  In patients treated with azacitidine, CR rate is 17%, PR rate 12%, and hematological improvement (HI) including possible CR and PR is 49%. […] The prognosis of patients after the failure of azacitidine treatment is poor, with median survival of c.6 months. […] In recent years, many clinical trials with the use of new molecules have been conducted in patients with myelodysplastic syndromes. After many years without new effective drugs, the latest results of phase II and III studies are generating optimism regarding the addition of new agents to what is still a relatively modest armamentarium.

• #2 Myelodysplastic Syndrome (MDS) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

  Drugs used to treat MDS include Azacitidine, Decitabine, and Lenalidomide. […] Azacitidine is a pyrimidine nucleoside analog. Azacitidine prolongs overall survival compared with supportive care and conventional chemotherapy. Median survival in patients with all subgroups of MDS treated with azacitidine is 21 months. Patients should be treated for at least of 4 to 6 cycles and continue for as long as the patient continues to benefit. […] Decitabine is also a pyrimidine nucleoside analog. It induces remission in as many as 43% of patients with MDS. It is indicated for treatment of patients with MDS of all subtypes. […] Azacitidine and decitabine are epigenetic modulators that hypomethylate DNA. Hypermethylation of certain regions of DNA appears to impair tumor suppressor genes and play a role in oncogenesis in MDS.

• #2 Treatment for Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/treatment

  For people with MDS who are not eligible for a stem cell transplant, Memorial Sloan Kettering offers the following treatment options: […] The US Food and Drug Administration approved 5-azacytidine for the treatment of MDS in 2004. […] Decitabine is FDA approved to treat MDS. […] Lenalidomide is FDA approved for only a relatively rare subtype of MDS with the chromosome 5 abnormality known as the deletion 5q abnormality. […] Another treatment approach is called immunosuppression. […] For people with MDS whose bone marrow has a large number of blast cells, doctors may use therapy for acute leukemia.

• #2 Myelodysplastic & Myeloproliferative Treatment | UVA Health

  https://uvahealth.com/services/blood-cancer/myelodysplastic-syndromes

  Depending on your condition and symptoms, you may need: […] […] If you need more aggressive treatment, you’ll have many options: […] […] Talk to your doctor to see if you qualify for one of our clinical trials. We offer trials for a wide range of MDS and MPN-related conditions with different leukemia-risk levels.

• #2 Myelodysplastic Syndrome Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/myelodysplastic-syndrome-pharmacologic-treatment/

  Treatment for MDS primarily centers on supportive or palliative care, which focuses on treating symptoms and improving quality of life for patients as opposed to treating MDS directly. […] For patients who require further treatment, pharmacologic options typically take the form of chemotherapy or immunosuppressive therapy. […] Luspatercept is used to treat anemia in adult patients with beta thalassemia, and for anemia that fails to respond to erythropoiesis-stimulating agents in adult patients with very low- to intermediate-risk MDS with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). […] Chemotherapy is typically reserved for patients with MDS in low-risk categories who are deemed unlikely to respond well to immunosuppressive therapy or who experience significant symptoms, as well as for patients in high-risk categories to slow or prevent the progression of MDS into AML.

• #2 How I Treat Anemia Associated with Lower-Risk Myelodysplastic Syndromes

  https://jhoponline.com/issue-archive/2021-issues/june-2021-vol-11-no-3/how-i-treat-anemia-associated-with-lower-risk-myelodysplastic-syndromes

  Lenalidomide is a first-line treatment option for patients with MDS associated with symptomatic anemia and chromosomal del 5q, with or without additional cytogenetic abnormalities. […] ESAs can be considered for the treatment of patients with lower-risk MDS and symptomatic anemia whose serum erythropoietin level is 500 U/L. […] The recombinant fusion protein luspatercept-aamt binds to select endogenous transforming growth factor beta superfamily ligands, thereby reducing SMAD2 and SMAD3 signaling. […] Red blood cell transfusions are recommended for patients with MDS and symptomatic anemia (ie, shortness of breath, weakness, fatigue, chest pain). […] The use of iron chelation therapy in patients with iron overload caused by frequent transfusions was recently supported in the TELESTO clinical trial of patients with low-risk or intermediate-1-risk MDS. […] The management of lower-risk MDS and associated anemia is largely focused on supportive care. Treatment options have recently expanded with the approval of luspatercept, which can reduce transfusions in select MDS morphologies.

• #2 Treating myelodysplastic syndrome (MDS) : University College London Hospitals NHS Foundation Trust

  https://www.uclh.nhs.uk/our-services/find-service/cancer-services/blood-diseases-clinical-haematology/blood-diseases-types-and-services/blood-cancers/myelodysplastic-syndrome-mds/treating-myelodysplastic-syndrome-mds

  Drugs such as anti-thymocyte immunoglobulin (ATG) and ciclosporin reduce the activity of the immune system, allowing your bone marrow to make blood cells. It can also help to control symptoms. However, these drugs are not suitable for everyone and work best in young people and those who don’t have a chromosome change associated with their condition. […] MDS patients may present with lower risk disease and then over time evolve to higher-risk disease. Alternatively, MDS patients may present at a time when their disease is already in a higher risk category. We have several treatment options available for patients with higher risk disease: […] Azacitidine is approved by the National Institute for Health and Care Excellence (NICE) for the treatment of MDS patients who are not eligible for a stem cell transplant. Azacitidine is a type of chemotherapy that works by altering the DNA of the MDS cells (called a hypomethylating agent). It is given by injections under the skin for seven days each month. The treatment is given on an outpatient basis.

• #2 New Treatment Approved for Certain Patients Living With Myelodysplastic Syndromes < Yale School of Medicine

  https://medicine.yale.edu/news-article/new-treatment-approved-for-certain-patients-living-with-myelodysplastic-syndromes/

  The U.S. Food and Drug Administration has approved imetelstat (known commercially as RYTELO) to treat some patients with the rare blood cancer, myelodysplastic syndromes (MDS). […] The trial showed that imetelstat, a first-in-class telomerase inhibitor, leads to durable independence from red blood cell transfusions and a significant improvement in anemia for heavily transfused lower-risk MDS patients. […] RYTELO is for adult patients with low- to intermediate-1 risk MDS, who are transfusion-dependent and require four or more red blood cell units over eight weeks. […] The new treatment aims to impede cancer growth for these patients with MDS, which affects mostly adults over 60 who are male.

• #2 https://www.lls.org/myelodysplastic-syndromes/treatment

  https://www.lls.org/myelodysplastic-syndromes/treatment

  Every patients situation should be evaluated individually by a hematologist-oncologist who specializes in treating MDS and who will discuss the disease subtype, prognostic factors and treatment options with the patient. It is also important to seek treatment at a center that has experience in treating MDS. […] Doctors use several types of approaches and treatment combinations for MDS: […] Your doctor may suggest that you participate in a clinical trial. Clinical trials can involve therapy with new drugs and new drug combinations or new approaches to stem cell transplantation. […] The treatment your doctor recommends is based on several factors, including: […] Because lower-risk MDS is more likely to progress slowly, low-intensity treatments are generally used first. […] High-risk MDS tends to grow quickly and progress to AML within a shorter time. For this reason, more intensive treatments are generally used. […] Ivosidenib (Tibsovo) is approved to treat adult patients whose disease has an IDH1 mutation and has returned after prior successful treatment or has stopped responding to active treatment.

• #2 Treatment for myelodysplastic syndrome (MDS) – NHS

  https://www.nhs.uk/conditions/myelodysplastic-syndrome-mds/treatment/

  Chemotherapy uses medicines to kill cancer cells. It’s one of the main treatments for higher risk MDS. […] You might have chemotherapy before having a stem cell transplant (called intensive chemotherapy). […] A stem cell transplant replaces the damaged stem cells in your bone marrow with healthy ones from a donor. It can sometimes cure MDS, but it’s not suitable for everyone. […] Immunosuppressants are medicines that reduce the activity of your immune system. They can be used to treat certain types of MDS. […] Targeted medicines kill cancer cells. Immunotherapy is where medicines are used to help your immune system kill cancer. […] You may also need to have supportive treatment to prevent or control symptoms caused by MDS. […] If you have advanced MDS it might be very hard to treat. It may not be possible to cure the cancer. […] If this is the case, the aim of your treatment will be to limit the cancer and its symptoms, and help you live longer.

• #2 Treating myelodysplastic syndrome (MDS) : University College London Hospitals NHS Foundation Trust

  https://www.uclh.nhs.uk/our-services/find-service/cancer-services/blood-diseases-clinical-haematology/blood-diseases-types-and-services/blood-cancers/myelodysplastic-syndrome-mds/treating-myelodysplastic-syndrome-mds

  This involves taking drugs that destroy the immature blood cells by disrupting their growth. The drugs are usually given by injection and require you to stay in hospital for a few weeks. […] The only way to cure MDS is to have intensive treatment with a stem cell transplant from a donor but this isn’t suitable for everyone. […] Lenalidomide is a drug that modulates the immune system. This drug appears to have a very specific effect in patients with MDS who have an abnormality in the chromosomes of the bone marrow called an isolated deletion 5q. Lenalidomide is taken by mouth and is given for 21 days out of every month. […] The treatment of MDS is constantly evolving and new drugs are being tested all the time. We are currently a number of clinical trials for new therapeutic agents in MDS.

• #2 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Treatments to get rid of unhealthy blood cells may include: Chemotherapy: Healthcare providers may use the same chemotherapy that’s used to treat AML. Immunosuppressive therapy: Providers may use this treatment for certain MDS subtypes. Immunosuppressive therapy suppresses overactive immune systems and may help reduce the need for transfusions. Stem cell transplant: Stem cell transplants replace your blood-forming cells with stem cells obtained from your blood or bone marrow or a donor’s blood or bone marrow. […] The only cure for MDS is a successful stem cell transplant. Unfortunately, not everyone can have this treatment.

• #2 Myelodysplastic Syndromes Treatment (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK66015/

  Lower-risk patients (conventionally defined as International Prognostic Scoring System (IPSS) low-risk and intermediate-1 risk groups) who have failed to respond or have ceased responding to ESAs may be treated with one of several disease-modifying agents. The impact of this practice on survival in lower-risk patients is unknown. […] The U.S. Food and Drug Administration (FDA) approved lenalidomide for the treatment of lower-risk, transfusion-dependent patients with MDS who harbor a del(5q) cytogenic abnormality. […] Allogeneic HSCT is the only potentially curative treatment for MDS. Retrospective data suggest cure rates in selected patients ranging from 30% to 60%; outcomes varied with IPSS score at time of transplant, with inferior survival in patients with higher IPSS scores. […] Induction chemotherapy typically used to treat AML may be used to treat patients with higher-risk MDS with excess blasts.

• #2 Treatment recommendations developed by MDS experts of the Polish Adult Leukemia Group (PALG) for management of myelodysplastic syndromes (MDSs) and other MDS-related conditions in Poland for 2021 | Mądry | Acta Haematologica Polonica

  https://journals.viamedica.pl/acta_haematologica_polonica/article/view/AHP.a2022.0009

  In non-responding patients or after loss of response to ESA some efficacy is shown by: lenalidomide, immunosuppressants, hypomethylating agents (HMA), luspatercept, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in selected cases. […] Despite the undoubted progress in the treatment of patients with MDS in recent years, allo-HSCT remains the only potentially curative method. […] The long-term outcome of allo-HSCT in MDS patients and the peri-transplant risk have been assessed in several prognostic indices, among which the predictive model by Della Porta et al. (based on age, HCT-CI, karyotype, IPSS-R and response to induction chemotherapy) and the so-called European Group for Blood and Marrow Transplantation (EBMT) transplant-specific risk score for MDS, are the most widely used.

• #2 Myelodysplasia or myelodysplastic syndrome (MDS) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/blood-cancer/myelodysplasia-mds

  Myelodysplasia (MDS) is a type of blood cancer that affects the bone marrow. […] Treatment for myelodysplasia (MDS) involves a team of health professionals working together to plan the best treatment for the patient. […] Your doctor will talk with you about treatment options. Treatments may be used to help with symptoms or reduce the risk of complications of MDS. This is called supportive treatment. […] Treatment can also be used to help control MDS. Less commonly, the aim of treatment may be to try to cure MDS. […] If you have very low-risk, low-risk or intermediate-risk MDS without symptoms, you may not need treatment straight away. Instead, you have regular check-ups and your blood count is monitored. This is sometimes called active monitoring or watch and wait. […] Supportive treatment aims to help treat symptoms and reduce the risk of complications caused by MDS.

• #2 Myelodysplastic Syndrome (MDS) – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

  Lenalidomide is an immunomodulator that is effective in reducing red blood cell transfusion requirements in patients with MDS with deletion 5q syndrome. […] In patients with hypoplastic MDS, immunosuppression with cyclosporine with or without antithymocyte globulin (ATG) has been effective, as evidenced by cell count improvement and decreased need for transfusion. […] Allogeneic hematopoietic stem cell transplantation is the only curative treatment for MDS. Allogeneic hematopoietic stem cell transplantation is indicated in younger, medically fit patients generally in intermediate-2 and high risk groups.

• #2

  https://haematologica.org/article/view/11858

  Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. […] While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient. […] Hypomethylating agents currently remain the only approved non-transplant option for higher-risk MDS and are the standard of care for patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). […] The only potential cure and standard of care for eligible patients is HSCT and even though the number of transplanted especially older MDS patients has increased over time due to better management and greater donor availability, the majority of MDS patients will not be eligible for this curative approach.

• #2 Myelodysplastic syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Myelodysplastic_syndrome

  Treatment may include supportive care, drug therapy, and hematopoietic stem cell transplantation. […] Supportive care may include blood transfusions, medications to increase the making of red blood cells, and antibiotics. […] Drug therapy may include the medications lenalidomide, antithymocyte globulin, and azacitidine. […] Some people can be cured by chemotherapy followed by a stem-cell transplant from a donor. […] For those with high risk MDS (characterized by an IPSS score greater than 3.5), the hypomethylating agent azacitidine showed increased survival compared to standard care (supportive care, cytarabine or chemotherapy) and is considered the standard of care. […] Azacitidine had increased survival (24 months vs 15 months) and higher rates of partial or complete therapeutic response (29% vs 12%) as compared to conventional care.

• #2 3 Innovative Myelodysplastic Syndrome Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/myelodysplastic-syndrome/myelodysplastic-syndrome-treatment.html

  Lower-risk myelodysplastic syndrome patients are treated initially for the specific complications of the disease, such as anemia and low blood counts. If more aggressive therapy is needed, strategies that are considered standard of care include chemotherapy using hypomethylating agents (5-azacitidine and decitabine) and lenalidomide. […] Higher-risk myelodysplastic syndrome patients usually need more aggressive therapy, but much depends on the age and condition of the patient. Younger patients with high-risk disease are considered for front-line chemotherapy approaches followed perhaps by allogeneic stem cell transplantation. […] For older patients, intensive chemotherapy is rarely considered. Instead, our strategy focuses on development of active and safe treatments for newly diagnosed patients as well as those for whom the standard of care based therapies has not been effective.

• #2 Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape

  https://www.mdpi.com/1718-7729/31/4/148

  Erythropoietin (EPO), an ESA, is an established treatment modality for anemia in patients with lower-risk MDS. […] Lenalidomide is an immunomodulatory agent with multiple mechanisms of action and is effective in the presence of del(5q). […] Hypomethylating agents (HMAs) are currently used in AML for transplant-ineligible patients who are not candidates for intensive chemotherapy. HMA therapy is also well established as frontline treatment in patients with high-risk MDS, as discussed in subsequent sections. […] Allo HSCT remains the only potentially curative treatment option for MDS and is the recommended standard of care for any suitable higher-risk candidate. […] With ongoing research, we anticipate that clinical, laboratory and molecular data will be increasingly utilized in clinical decision making, ultimately leading to more effective and less toxic targeted interventions as we work to decrease morbidity and improve survival for our patients with MDS.

• #2 Myelodysplastic Syndromes Treatment – NCI

  https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq

  Patients who were treated in the past with chemotherapy or radiation therapy may develop myeloid neoplasms related to that therapy. Treatment options are the same as for other myelodysplastic syndromes. […] There is no standard treatment for refractory or relapsed myelodysplastic syndromes. Patients whose cancer does not respond to treatment or has come back after treatment may want to take part in a clinical trial.

• #2 Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome

  Treatment for Myelodysplastic Syndrome (MDS) […] MSKs Hematology Disease Management team cares for more than 125 people diagnosed with MDS each year. Our experts in MDS run research studies, also known as clinical trials, to evaluate the latest treatments. […] MSK has been named a Center of Excellence by the Myelodysplastic Syndromes Foundation.

• #2

• #2 Myelodysplastic Syndromes (MDS) Care | UC San Diego Health

  https://health.ucsd.edu/care/cancer/cancers-we-treat/leukemia-lymphoma/mds/

  Moores Cancer Center is an MDS Center of Excellence, designated by the Myelodysplastic Syndromes Foundation. […] Patients at an MDS Center of Excellence receive the highest level of care throughout their cancer journey, including: […] State-of-the-art genetic testing to personalize treatment options […] Depending on whether you have a low-risk or high-risk form of MDS, your care plan may include one or more of the following: […] Growth factor therapy to increase red blood cell production (usually erythropoietin or granulocyte colony-stimulating factor) […] Lenalidomide (Revlimid) for those with chromosome 5q deletion […] Azacitidine (Vidaza), or decitabine (Dacogen) for high-risk disease […] Blood and marrow transplantation (BMT) […] Rafael Bejar, MD, PhD, is a physician-scientist who both cares for MDS patients and runs a research laboratory dedicated to studying MDS.

• #2 Myelodysplastic Syndromes | Symptoms, Treatments, FAQs | LLS

  https://www.lls.org/myelodysplastic-syndromes/myelodysplastic-syndromes

  Hematologists and oncologists are specialists who treat people who have MDS or other types of blood cancer. […] Treatment outcomes vary widely among patients; results depend on many individual factors. […] Seek treatment in a cancer center where doctors are experienced treating patients with MDS. […] Ask your doctor whether a clinical trial is a good treatment option for you.

• #2 Treatment for Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/treatment

  If you have been diagnosed with myelodysplastic syndrome (MDS), Memorial Sloan Kettering doctors will devise a course of treatment specific to you. We will take a number of factors into consideration, including: […] If you have been diagnosed with MDS, you may be able to receive a stem cell transplant, also called a bone marrow transplant. It has the potential to cure MDS. […] Stem cell transplants may be considered as a treatment option if you are below the age of 75 and are otherwise healthy. […] Supportive care is the cornerstone of all MDS treatments. Its goal is to help alleviate or prevent symptoms from low blood counts. […] Treatments may help improve blood counts temporarily and reduce or eliminate symptoms from low blood counts. They do not fix the underlying cause of MDS.

• #2 Myelodysplastic Syndromes | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/myelodysplastic-syndromes

  Many kinds of treatments are available for MDS, including new medications and stem cell transplantation. […] The combination of high-dose chemotherapy and an allogeneic stem cell transplant (stem cells from a donor) is currently the only cure for this condition. […] Other treatments aim to relieve symptoms and improve quality and length of life. […] The only known cure for MDS is allogeneic blood and marrow transplantation (BMT). […] If allogeneic BMT is not appropriate for a patient, treatment is geared toward relieving symptoms, reducing the need for transfusions, deferring conversion to acute myeloid leukemia, and improving the quality and length of life. It does not aim to achieve a cure. […] The major treatment strategies are: Supportive care, Epigenetic therapy, Biologic therapy.

• #3 Diagnosis and Treatment of Myelodysplastic Syndromes: A Review – PubMed

  https://pubmed.ncbi.nlm.nih.gov/36066514/

  Treatments are tailored to the patient’s disease characteristics and comorbidities and range from supportive care with or without erythropoiesis-stimulating agents for patients with low-risk MDS to hypomethylating agents, such as azacitidine or decitabine, for patients with higher-risk MDS. Hematopoietic cell transplantation is potentially curative and should be considered for patients with higher-risk MDS at the time of diagnosis.

• #3 Tests and treatment for myelodysplastic syndrome | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/myelodysplastic-syndromes/treatment

  You may have transfusions to treat your MDS. You have a drip containing red blood cells if your red blood cells are low. If your platelets are low you have a drip of a clear fluid containing platelets. […] Growth factors are drugs that encourage your bone marrow to make more blood cells. We know from research that this can reduce the number of blood transfusions you need. […] Sometimes with MDS, white blood cells called T lymphocytes affect normal blood cell production. Immunosuppressant drugs work by making T lymphocytes less active. […] Chemotherapy uses drugs to destroy the immature cells. The drugs work by disrupting the growth of cells and stopping them from dividing. […] When you have a stem cell transplant using another persons (donor) stem cells, it is called an allogeneic transplant.

• #3 Get Treatment for Myelodysplastic Syndromes | Cleveland Clinic

  https://my.clevelandclinic.org/services/myelodysplastic-syndromes-treatment

  Some people with MDS have low levels of neutrophils (a type of white blood cell). […] Your care team may also recommend blood cell growth factor medication to increase the number of red and white blood cells and platelets in your blood. […] You may need a blood transfusion to replace unhealthy blood cells with cells from a healthy donor. […] Immunosuppressants and immunomodulators may help people with low-risk MDS. […] Chemotherapy drugs destroy cancer cells but also have side effects. […] We may recommend a stem cell transplant of healthy blood-forming cells from a donor or from your own blood. […] A successful stem cell transplant is the only known treatment that can potentially cure myelodysplastic syndromes. […] Myelodysplastic syndrome is a chronic (ongoing) cancer. […] Cleveland Clinic offers many ways to support you and your loved ones with counseling, support groups and more. […] Getting treatment as quickly as possible with caring providers you trust can improve your results.

• #3 MDS Treatment | The University of Kansas Cancer Center | Kansas City

  https://www.kucancercenter.org/cancer/cancer-types/myelodysplastic-syndromes/myelodysplastic-syndromes-treatments

  Medications that improve bone marrow function by freeing up genes your body uses to make normal blood cells. These include medications such as 5-azacytidine (Vidaza) and decitabine. With the help of these medications, blood counts increase, which can help the number of immature blood stem cells return to normal. This decreases or delays the likelihood of leukemia. […] Immunosuppressant medications. This treatment uses antithymocyte globulin (ATG) to suppress the activity of white cells that, in some cases of MDS, interfere with normal blood cell production. This approach works temporarily in less than half of patients, however. […] Medications to compensate for a genetic abnormality in blood cell production. Lenalidomide (Revlimid) has been effective in treating a very specific chromosome abnormality and improving hemoglobin levels.

• #3 3 Innovative Myelodysplastic Syndrome Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/myelodysplastic-syndrome/myelodysplastic-syndrome-treatment.html

  Lower-risk myelodysplastic syndrome patients are treated initially for the specific complications of the disease, such as anemia and low blood counts. If more aggressive therapy is needed, strategies that are considered standard of care include chemotherapy using hypomethylating agents (5-azacitidine and decitabine) and lenalidomide. […] Higher-risk myelodysplastic syndrome patients usually need more aggressive therapy, but much depends on the age and condition of the patient. Younger patients with high-risk disease are considered for front-line chemotherapy approaches followed perhaps by allogeneic stem cell transplantation. […] For older patients, intensive chemotherapy is rarely considered. Instead, our strategy focuses on development of active and safe treatments for newly diagnosed patients as well as those for whom the standard of care based therapies has not been effective.

• #3 Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics

  Although there is a significant chance of cure after stem cell transplantation, transplant-related deaths, and relapse can still occur. Because of the balance of risks (GVHD and other toxicity) and benefits (longer survival and possible cure), transplantation is usually suggested only for people with higher-risk MDS. It is generally not suggested for people with lower-risk MDS because of their better overall prognosis. The upper age limit for transplantation is generally 75 years old. However, fitness is probably at least as important as age, and new methods for transplantation are making it available to a broader range of ages and levels of medical fitness. You should talk to a transplantation expert about whether you may be a candidate for some form of transplantation.

• #3 Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics

  People with lower-risk MDS are generally treated with low-intensity therapy or supportive care alone. […] Treatment of people with higher-risk MDS may vary according to age, overall health, and personal preference: […] People who are less than about 75 years old and otherwise healthy may be treated with low- or high-intensity therapies. […] People who are about 75 years or older or less medically fit may be treated with low-intensity therapy or supportive care alone. However, there is no absolute age cut-off at which high-intensity therapy is no longer recommended. […] There is great interest in clinical trials for improving treatment of MDS. […] LOW-INTENSITY TREATMENTS […] Low-intensity chemotherapy—Certain classes of drugs, or low doses of drugs from other classes, may be suggested for people with lower-risk MDS, or for people with higher-risk MDS who cannot tolerate high-intensity treatments. The goal is to enable bone marrow cells to develop more normally and allow improved production of red blood cells, white blood cells, and platelets. Drugs used in this situation include luspatercept, imetelstat, azacitidine, decitabine, decitabine/cedazuridine, and lenalidomide.

• #3 Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/myelodysplastic-syndromes-mds-in-adults-beyond-the-basics

  HIGH-INTENSITY TREATMENTS […] High-intensity chemotherapy—People with higher-risk MDS may be treated with low-intensity chemotherapy drugs azacitidine, decitabine, or decitabine/cedazuridine, or with chemotherapy similar to that used for treating acute myeloid leukemia (AML). Chemotherapy is used to destroy abnormal cells or prevent them from growing. For people who are eligible, this may be followed by a stem cell transplant because intensive chemotherapy alone is unlikely to cure MDS. […] Stem cell transplantation—Stem cell transplantation (also called hematopoietic cell transplantation or bone marrow transplantation) is the treatment for MDS most associated with long-term survival, although long-term survivors can have complications such as „graft-versus-host disease” (GVHD). As with all therapies, the potential risks of transplant must be considered together with the potential benefits relative to other treatment options.

• #3 Myelodysplastic Syndrome (MDS): Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/cancer/blood-cancer/myelodysplastic-syndrome-mds/treatment

  Treatment options will be tailored to the individual, including bone marrow transplants, blood transfusions, and specific medications. […] A bone marrow transplant (or stem cell transplant) is currently the only treatment option that may cure MDS for some people. The procedure presents a high risk of developing serious complications. A bone marrow transplant is typically only performed on those healthy enough to endure it. […] Blood transfusions involve using healthy donor blood cells to replace unhealthy platelets and red blood cells. Blood transfusions can help with symptoms of MDS. […] Medication is often used to address the symptoms of myelodysplastic syndrome subtypes. The goal of MDS medications can be to: […] These are only some of the medications available to treat Myelodysplastic syndrome. Please consult your doctor for a full list of available treatments.

• #4 Supportive Therapy for Myelodysplastic Syndromes

  https://www.healthline.com/health/myelodysplastic-syndromes-supportive-therapy-expert-answers

  Supportive therapies in MDS means treatments that help with the complications of the disease rather than treating the disease itself. […] In MDS, the body doesnt fight off MDS by itself. But there are supportive therapies in MDS to help reduce the chance that patients get symptoms from one of the complications from MDS, including transfusion of blood products, treatments to reduce the iron buildup in the blood from multiple transfusions, and antibiotics. […] Supportive therapies in MDS include: Blood transfusions: These can be done to increase either red blood cells (to treat anemia) or platelets (to help prevent bleeding). […] Without supportive treatments, people with MDS would succumb to the disease much sooner than expected due to severe anemia. […] Supportive therapy is essential in the MDS treatment plan because both the disease and the treatment itself can cause complications of anemia, bleeding, or increase the chance of having an infection.

Zobacz więcej